Αρχική World News Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal Junction...

Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal Junction Cancer

In CheckMate 577 study conducted among patients with resected oesophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy, adjuvant therapy with nivolumab was associated with a significantly longer disease-free survival (DFS) than placebo. The safety profile of nivolumab was similar to that seen in other solid tumours. It is the second tumour type, after melanoma, for which nivolumab has provided a benefit in the adjuvant setting. Dr. Ronan J. Kelly of the Baylor University Medical Center in Dallas, TX, US and colleagues published the CheckMate 577 findings on 1 April 2021 in The New England Journal of Medicine.

The authors wrote in the study background that the incidence of oesophageal and gastroesophageal junction adenocarcinomas continues to increase in Western countries. The risk of recurrence after neoadjuvant chemoradiotherapy and surgery is high, especially among the 70-75% of patients who do not have a pathological complete response (pCR). The median overall survival among patients without a pCR is shorter than that among those with a pCR, and outcomes are even worse in patients with lymph node–positive disease.

The CheckMate 577 is a global, randomised, double-blind, placebo-controlled phase III study that evaluated adjuvant treatment with nivolumab after neoadjuvant chemoradiotherapy and surgery for oesophageal or gastroesophageal junction cancer. Patients with resected stage II or III oesophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy and had residual pathological disease were randomly assigned in a 2:1 ratio to receive adjuvant nivolumab or placebo. The primary endpoint was DFS.

The median follow-up was 24.4 months. Among the 532 patients who received nivolumab, the median DFS was 22.4 months (95% confidence interval [CI] 16.6 to 34.0), as compared with 11.0 months (95% CI 8.3 to 14.3) among the 262 patients who received placebo (hazard ratio [HR] for disease recurrence or death 0.69; 96.4% CI 0.56 to 0.86; p < 0.001).

Distant recurrence was less frequent in the nivolumab group than in the placebo group (29% and 39%, respectively), as was locoregional recurrence (in 12% and in 17%, respectively). A greater benefit of nivolumab than placebo was observed in patients with squamous cell cancer (HR 0.61) than in those with adenocarcinoma (HR 0.75). Benefit was also reported in patients with node-negative disease (HR 0.74) and node-positive disease (HR 0.67), across tumour stages, in patients with HER2-positive (HR 0.78) and HER2-negative disease (HR 0.69), in patients with tumours that were PD-L1–negative (HR 0.73) and PD-L1–positive (HR 0.75).

The median distant metastasis–free survival was 28.3 months (95% CI 21.3 to could not be estimated) in the nivolumab group and 17.6 months (95% CI 12.5 to 25.4) in the placebo group; thus, the risk of distant recurrence or death was 26% lower with nivolumab than with placebo (HR 0.74; 95% CI 0.60 to 0.92).

Grade 3 or 4 adverse events occurred in 13% of the patients in the nivolumab group and 6% in the placebo group. The study regimen was discontinued because of adverse events in 9% of the patients in the nivolumab group and 3% of those in the placebo group.

The study team reported that health-related quality of life was maintained during the treatment period.

Dr. David H. Ilson of the Memorial Sloan Kettering Cancer Center in New York, NY, US wrote in an accompanied article that patients with tumour in oesophagus had greater benefit (HR 0.61) than those with tumours of the gastroesophageal junction (HR 0.87). Furthermore, he commented that improvement in survival among patients with oesophageal cancer has been long awaited in those undergoing chemotherapy, radiation and surgerical treatment, so CheckMate 577 study results provide a new therapeutic option for these patients 

The study was supported by Bristol Myers Squibb and Ono Pharmaceutical.

References

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Puppy That Was Born Dead Becomes Therapy Dog for Cancer Patient

This story has been shared as part of the Fur Fam Story Contest. You can submit your own tale through December 5th. Voting will...

ESMO Immuno-Oncology Congress 2021, Geneva, Switzerland, 8-11 December

LUGANO, Switzerland – The ESMO Immuno-Oncology Congress 2021, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held...

Targeted drug recommended to treat some advanced lung cancer patients

Selpercatinib will expand treatment options available for people with RET fusion positive non small cell lung cancer. Non small cell lung cancer cells. The National Institute...

Withdrawal of Application to Change the EU Marketing Authorisation for Cervarix

The European Medicines Agency (EMA) announced on 12 November 2021 that GlaxoSmithKline Biologicals SA withdrew its application to use Cervarix (human papillomavirus vaccine ...

Robin Williams Required Film Companies He Worked With To Hire Homeless People

It’s been years since his passing, but the world still feels the loss of Robin Williams. Not only was he an extremely talented and funny...

Though the Pandemic Has Slowed, Many Are Still Struggling to Put Food on the Table

The COVID-19 pandemic wreaked havoc on the economy, leaving many people who had been comfortable suddenly struggling financially. Feeding America estimates that at least...